EGFR and non-small cell lung carcinoma: The treatment was well-tolerated with no significant adverse events observed during the follow-up periodstoryliter.<h4>Conclusion</h4>This case suggests that ivonescimab monotherapy can achieve disease control with an acceptable safety profile in an elderly, heavily pretreated NSCLC patient with EGFR-TKI resistance and malignant pericardial effusion.